BSE Ltd
Investment Thesis
Over a 3-5 year horizon, BSE Ltd. will achieve sustained revenue growth and market share gains in non-derivatives segments, driven by the financialization of savings, increasing retail investor participation, and successful diversification into mutual fund distribution and SME listings, while maintaining its strong financial profile.
Conviction History
Assumptions
BSE Star MF transaction volumes will grow at a compound annual growth rate (CAGR) of over 20% and SME listings will increase by at least 25% annually through FY2028, driven by financialization trends and supportive SEBI policies.
BSE's average daily trading volume in the cash equity segment will grow at a CAGR of at least 15% through FY2028, outperforming general market growth and capturing increased retail participation.
BSE will maintain a debt-free balance sheet throughout the forecast period, with total debt remaining at 0x EBITDA.
BSE will maintain consolidated operating profit margins above 58% through FY2028, supported by stable technology infrastructure costs and pricing power in data dissemination and listing services.
Annual capital expenditure will range between INR 150-200 crore, primarily directed towards technology upgrades and platform development to support growth initiatives and maintain competitive infrastructure.
No material regulatory sanctions or governance failures will occur that lead to significant operational disruption or reputational damage, beyond minor procedural lapses noted regarding remuneration disclosures.
Recent Developments
Sebi approves 4 IPOs including Integris Medtech, Alpine Texworld and Anjali Labtech
SEBI approved four new IPOs, including Integris Medtech (Rs 925 crore) and Alpine Texworld, to list on the BSE, strengthening the primary market pipeline.
RBI tightened capital market exposure norms requiring bank guarantees to be backed by 50% collateral and banning bank funding for proprietary trading effective April 2026.
BSE, Angel One shares fall up to 10% after RBI tightens capital market exposure norms
RBI tightened capital market exposure norms effective April 2026, requiring bank guarantees to exchanges be backed by 50% collateral and banning bank funding for proprietary trading.
IPO Calendar: Gaudium IVF to open next week as Fractal, Aye Finance head for listing
BSE Q3 FY26 PAT surged 174% to Rs 602 crore, driven by record equity derivatives volume and 87.4% market share in mutual fund transactions.
BSE gets Sebi nod to launch 'Focused Midcap Index' futures and options contracts
SEBI approved BSE to launch 'Focused Midcap Index' derivatives; HUL demerger of Kwality Wall's (2.3B shares) confirmed for listing on Feb 16.
BSE Q3 Results: Cons PAT skyrockets 174% YoY to Rs 602 crore, revenue soars 62%
Q3 FY26 PAT surged 174% YoY to Rs 602 crore, driven by an 86% increase in transaction revenue from derivatives scaling.
IPO Calendar This Week: Aye Finance, Fractal Analytics among major issues - Full list - ET Now
BSE to list Aye Finance (Rs 1,010 cr) and Marushika Technology, signaling robust IPO volume and SME segment momentum.